Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target

$240.01 +2.24 (+0.94%)

As of 04:00 PM Eastern

Alnylam Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 26 Analyst Ratings

Sell
1

Hold
4

Buy
21

Based on 26 Wall Street analysts who have issued ratings for Alnylam Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 4 have given a hold rating, and 21 have given a buy rating for ALNY.

Consensus Price Target

$315.58
31.49% Upside

According to the 26 analysts' twelve-month price targets for Alnylam Pharmaceuticals, the average price target is $315.58. The highest price target for ALNY is $500.00, while the lowest price target for ALNY is $159.00. The average price target represents a forecasted upside of 31.49% from the current price of $240.01.

Get the Latest News and Ratings for ALNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors.

ALNY Analyst Ratings Over Time

Type	Current Forecast 4/14/24 to 4/14/25	1 Month Ago 3/15/24 to 3/15/25	3 Months Ago 1/15/24 to 1/14/25	1 Year Ago 4/15/23 to 4/14/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	21 Buy rating(s)	19 Buy rating(s)	19 Buy rating(s)	10 Buy rating(s)
Hold	4 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	8 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$315.58	$304.26	$298.61	$216.12
Forecasted Upside	31.49% Upside	25.85% Upside	24.16% Upside	45.53% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Remove Ads

ALNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Alnylam Pharmaceuticals Stock vs. The Competition

Type	Alnylam Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.77	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	31.49% Upside	25,211.73% Upside	25.94% Upside
News Sentiment Rating	Positive News See Recent ALNY News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/11/2025	Morgan Stanley 3 of 5 stars	Michael Ulz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$284.00 ➝ $268.00	+16.01%
4/9/2025	Needham & Company LLC 2 of 5 stars	Joseph Stringer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$320.00 ➝ $320.00	+42.65%
4/2/2025	HC Wainwright 1 of 5 stars	Patrick Trucchio Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$500.00 ➝ $500.00	+91.04%
3/31/2025	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	G. Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Sector Outperform ➝ Sector Outperform	$338.00 ➝ $342.00	+29.14%
3/31/2025	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joshua Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$353.00	+31.49%
3/31/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$300.00 ➝ $345.00	+28.51%
3/24/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$280.00 ➝ $328.00	+15.76%
3/21/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Lebovitz Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$338.00 ➝ $351.00	+25.02%
3/21/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$385.00 ➝ $390.00	+38.29%
3/21/2025	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$310.00 ➝ $330.00	+17.29%
Get the Latest News and Ratings for ALNY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
3/21/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
3/21/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tiago Fauth Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$275.00 ➝ $287.00	+13.17%
3/21/2025	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$300.00 ➝ $300.00	+18.30%
3/21/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$302.00 ➝ $325.00	+28.15%
1/7/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$314.00 ➝ $310.00	+31.53%
11/18/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$296.00 ➝ $296.00	+27.70%
11/12/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Peer Perform ➝ Underperform
11/1/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$275.00 ➝ $298.00	+10.74%
11/1/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$295.00 ➝ $329.00	+23.61%
10/21/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$282.00 ➝ $371.00	+25.37%
10/11/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$220.00 ➝ $220.00	-21.77%
8/16/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Richter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$198.00 ➝ $370.00	+40.85%
6/28/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Merle Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$253.00 ➝ $288.00	+18.37%
6/25/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform ➝ Market Perform	$138.00 ➝ $159.00	-33.15%
6/25/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$210.00 ➝ $260.00	+12.40%
6/24/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$234.00 ➝ $234.00	+3.28%
10/11/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
4/26/2023	Sumitomo Mitsui Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$220.00	+8.83%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:58 PM ET.

Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 8, 2025. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com.

Alnylam Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.:

The stock has a strong market capitalization of approximately $29.18 billion, indicating a solid position in the biopharmaceutical sector, which can attract institutional investors.
Recent analyst upgrades, including a target price increase from Stifel Nicolaus to $345.00, suggest a potential upside of 41.63% from the current stock price of $243.59, making it an attractive investment opportunity.
Alnylam Pharmaceuticals, Inc. has a high current ratio of 2.78, indicating strong liquidity and the ability to cover short-term liabilities, which is a positive sign for financial health.
Institutional ownership is at 92.97%, reflecting strong confidence from large investors in the company's future performance and stability.
The company is focused on innovative therapeutics based on ribonucleic acid interference, positioning it well in a growing market for advanced biopharmaceutical solutions.

Alnylam Pharmaceuticals
Bear Case

Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons:

The stock has a negative price-to-earnings ratio of -103.37, indicating that the company is currently not profitable, which can be a red flag for potential investors.
Recent insider selling, including significant transactions by the CFO and EVP, may signal a lack of confidence in the company's short-term prospects, which could concern investors.
The stock has experienced volatility, with a 12-month high of $304.39 and a low of $141.98, indicating potential risks associated with price fluctuations.
Despite a high market cap, the debt-to-equity ratio of 15.27 suggests that the company is heavily leveraged, which can increase financial risk, especially in uncertain market conditions.
Recent downgrades from some analysts, such as StockNews.com lowering the rating from "buy" to "hold," may indicate a cautious outlook on the stock's performance moving forward.

ALNY Forecast - Frequently Asked Questions

: According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Alnylam Pharmaceuticals is $315.58, with a high forecast of $500.00 and a low forecast of $159.00.
: 26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There is currently 1 sell rating, 4 hold ratings and 21 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares.
: According to analysts, Alnylam Pharmaceuticals's stock has a predicted upside of 31.49% based on their 12-month stock forecasts.
: Over the previous 90 days, Alnylam Pharmaceuticals's stock had 1 upgrade by analysts.
: Alnylam Pharmaceuticals has been rated by research analysts at Bank of America, Canaccord Genuity Group, Chardan Capital, Citigroup, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Redburn Atlantic, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, Wells Fargo & Company, and William Blair in the past 90 days.
: Analysts like Alnylam Pharmaceuticals less than other "medical" companies. The consensus rating score for Alnylam Pharmaceuticals is 2.77 while the average consensus rating score for "medical" companies is 2.82. Learn more on how ALNY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:ALNY) was last updated on 4/14/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alnylam Pharmaceuticals (ALNY) Stock Forecast & Price Target